The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a new microfluidic drug delivery device for in vivo testing of targeted chemotherapeutics and tumor susceptibility.
Cancer treatment planning remains an ongoing challenge to oncologists and patients alike, with each cancer being genetically unique and requiring personalized approaches. Greater outcome success will depend on highly individualized therapy selection as revealed through genomic profiling.

Clinical research demonstrates that localized tumor responses predict the benefit of systemic chemotherapy, reflecting outcomes in metastatic disease. Unfortunately, testing single drugs in vivo often involves systemic administration of drugs to determine patient response. Chemical toxicity remains a concern and is exacerbated by repeated trials of ineffective agents, with in vitro drug testing lacking effectiveness as an alternative. Finding optimal combinations may take several iterations with accompanying patient decline. Read the full story here.